SUPN Supernus Pharmaceuticals Inc

Price (delayed)

$30.315

Market cap

$1.66B

P/E Ratio

1,515.75

Dividend/share

N/A

EPS

$0.02

Enterprise value

$1.62B

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for ...

Highlights
The debt has dropped by 92% year-on-year
The quick ratio has soared by 52% YoY and by 16% from the previous quarter
The company's net income has shrunk by 98% YoY and by 95% QoQ
The EPS has dropped by 98% year-on-year and by 96% since the previous quarter

Key stats

What are the main financial stats of SUPN
Market
Shares outstanding
54.73M
Market cap
$1.66B
Enterprise value
$1.62B
Valuations
Price to book (P/B)
1.8
Price to sales (P/S)
2.72
EV/EBIT
312
EV/EBITDA
17.96
EV/Sales
2.66
Earnings
Revenue
$607.52M
EBIT
$5.18M
EBITDA
$90.04M
Free cash flow
$110.53M
Per share
EPS
$0.02
Free cash flow per share
$2.03
Book value per share
$16.87
Revenue per share
$11.14
TBVPS
$10.28
Balance sheet
Total assets
$1.28B
Total liabilities
$356.16M
Debt
$33.2M
Equity
$921.52M
Working capital
$202.92M
Liquidity
Debt to equity
0.04
Current ratio
1.7
Quick ratio
1.38
Net debt/EBITDA
-0.46
Margins
EBITDA margin
14.8%
Gross margin
86.2%
Net margin
0.2%
Operating margin
-1.1%
Efficiency
Return on assets
0.1%
Return on equity
0.1%
Return on invested capital
2.1%
Return on capital employed
0.5%
Return on sales
0.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SUPN stock price

How has the Supernus Pharmaceuticals stock price performed over time
Intraday
1.22%
1 week
4.53%
1 month
-12.18%
1 year
-19.61%
YTD
4.75%
QTD
-11.13%

Financial performance

How have Supernus Pharmaceuticals's revenue and profit performed over time
Revenue
$607.52M
Gross profit
$523.74M
Operating income
-$6.79M
Net income
$1.32M
Gross margin
86.2%
Net margin
0.2%
SUPN's operating income has plunged by 123% from the previous quarter and by 115% YoY
The company's operating margin has shrunk by 123% QoQ and by 116% YoY
The net margin has dropped by 98% year-on-year and by 95% since the previous quarter
The company's net income has shrunk by 98% YoY and by 95% QoQ

Growth

What is Supernus Pharmaceuticals's growth rate over time

Valuation

What is Supernus Pharmaceuticals stock price valuation
P/E
1,515.75
P/B
1.8
P/S
2.72
EV/EBIT
312
EV/EBITDA
17.96
EV/Sales
2.66
The EPS has dropped by 98% year-on-year and by 96% since the previous quarter
SUPN's price to book (P/B) is 11% less than its 5-year quarterly average of 2.0
Supernus Pharmaceuticals's equity has increased by 4% YoY
Supernus Pharmaceuticals's revenue has decreased by 9% YoY
The P/S is 3.9% below the 5-year quarterly average of 2.8

Efficiency

How efficient is Supernus Pharmaceuticals business performance
The company's return on equity has shrunk by 99% YoY and by 96% QoQ
The return on assets has dropped by 97% year-on-year and by 94% since the previous quarter
The return on sales has dropped by 91% year-on-year and by 87% since the previous quarter
SUPN's return on invested capital has dropped by 83% year-on-year and by 83% since the previous quarter

Dividends

What is SUPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SUPN.

Financial health

How did Supernus Pharmaceuticals financials performed over time
SUPN's current ratio has surged by 59% year-on-year and by 9% since the previous quarter
The company's total liabilities has shrunk by 56% YoY and by 4.5% QoQ
The debt is 96% smaller than the equity
The debt has dropped by 92% year-on-year
Supernus Pharmaceuticals's debt to equity has plunged by 92% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.